FDA
-
-
-
-
-
-
-
Melinta Therapeutics Says its Topical Radezolid Was Well Tolerated in Phase 1 Study for Treatment of Acne (CEMP)
-
-
-
-
-
-
-
Melinta Therapeutics to Participate in Two Upcoming Investor Conferences
-
-
-
-
-
-
-
Cempra (CEMP) Announces Eight Presentations at ASM Microbe
-
-
-
-
-
-
-
Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups
-
-
-
-
-
-
-
Cempra Retains Morgan Stanley to Lead Review of Strategic Business Options
-
-
-
-
-
-
-
Cempra’s Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI
-
-
-
-
-
-
-
Morgan Stanley Upgrades Cempra, Inc. (CEMP) to Equalweight
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

